ArticleInternational journal of legal medicine2025
Cardiac-specific troponin-I (cTnI) in a post-mortem setting.
Article in International journal of legal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-mortem cardiac-specific troponin-I (cTnI) to determine the cause of non-traumatic hemopericardium.Forensic science, medicine, and pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac-specific troponin (cTn) is widely used in clinical medicine to support a diagnosis of acute myocardial infarction. Several studies have explored the value of cTn testing in deceased individuals. These studies suggest that -although there are important limitations associated with its use- post-mortem cTn can be useful in selected cases. A decision for post-mortem cTn testing should however be influenced by factors that have not been explored in much detail. This includes the success rate of post-mortem cTn testing, and whether cTn levels are stable after death.Therefore, this study addresses the post-mortem availability and stability of cardiac-specific Troponin I (cTnI). Post-mortem availability was determined by analysing the success rate in 250 high-sensitivity (hs-)cTnI tests on post-mortem blood samples, and its relationship with variables such as sample location, sample type, post-mortem interval, and decomposition. Post-mortem stability was explored by comparing post-mortem cTnI levels between two samples from the same individual, taken at different times.Post-mortem hs-cTnI tests were successful in 86.4% of cases (216/250), with little effect of sex, age, or cardiopulmonary resuscitation. Visible decomposition precluded a successful test. Other variables associated with decomposition (such as increased post-mortem interval) also affected test success negatively. Our results furthermore suggest that cTnI is very unstable post-mortem, with marked differences in hs-cTnI test results between samples from the same individual. The differences were large (on average 18734 ng/L) and not unidirectional. Instability appeared to increase with larger time intervals, but the results were overall erratic and difficult to interpret.We conclude that hs-cTnI testing results are generally available in a post-mortem setting, but that testing should be performed on the earliest available blood sample. Samples from decomposed individuals should not be tested. Furthermore, the severe instability of cTnI indicates that any post-mortem hs-cTnI result must be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.